PCI Synthesis obtains DEA registration for controlled substance development and manufacturing

Published: 15-Sep-2016
Manufacturing Regulatory

Certification expands the company's capabilities to handle cGMP development for schedule II, III, IV and V


US Contract manufacturer PCI Synthesis has obtained registration and certification from the US Drug Enforcement Administration (DEA) to handle Schedule II, III, IV and V controlled substances. With DEA registration, the company will be able to work on projects that are considered controlled substances or the raw materials that are used to produce them.

'Expanding the type of substances we can work with positions PCI Synthesis to meet the growing demand for new molecules that make use of the medical value of controlled substances,' said Edward S. Price, president of PCI Synthesis. 'As a cGMP facility that has DEA certification, we can assure our sponsors that the work we do can take them from discovery all the way through commercialisation.'

In preparation for these new substances, the company has invested in new systems, processes and training so that it can manufacture controlled substances in its Newburyport facility. It has also conducted an audit by a third party to ensure PCI Synthesis is in compliance with the requirements to earn and maintain its DEA registration.

'DEA certification for these kinds of controlled substances opens a new dimension for PCI Synthesis in terms of the types of projects the company can pursue,' said Jim Bruno at Chemical and Pharmaceutical Solutions, a New Jersey-based consultancy. 'Once PCI Synthesis receives the DEA certification, it will be able to do R&D and move those projects into commercial production.'

PCI Synthesis, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as APIs, earlier this year announced that its commercially approved products portfolio now includes nine products that either have or are imminently receiving FDA approval for sale in the US. The company has more than 17 API and other advanced materials products in its commercial pipeline.

  • Companies:
  • Seqens
See more

You may also like

Manufacturing

Seqens isopropanol plant expansion

Read more
The plant has almost been completed and is due to be finalised as planned by end of Q1 2022

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer Denis will be responsible for optimising global operations for the company
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
  5. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Seqens isopropanol plant expansion

The plant has almost been completed and is due to be finalised as planned by end of Q1 2022
Manufacturing

PCI Synthesis establishes a cGMP Advanced Polymer Development and Manufacturing Group

The team has experience with developing polymeric materials for implantable medical devices, drug delivery technologies, therapeutics, excipients and medical grade coatings
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Initiating change in drug development and manufacture

With R&D and production costs spiralling and the growing regulatory requirements biting into the profit margins of drug sales, the industry needs radical change to manufacturing models, argues Ed Price, President, PCI Synthesis
Manufacturing

PCI Synthesis earns top Life Science Leader awards for second year in a row
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

GDUFA – the promise and the reality

The introduction of GDUFA was meant to reduce a regulatory backlog and improve patient safety. Edward Price, President, PCI Synthesis, argues it has, in fact, had a more far-reaching impact
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Manufacturing

INEOS Nitriles launches INVIREO - the first bio-based acetonitrile

The company has released INVIERO, an acetonitrile capable of significantly reducing the carbon footprint of manufacturing processes
Subscribe now